Washington University School of Medicine

Digital Commons@Becker
ICTS Faculty Publications

Institute of Clinical and Translational Sciences

2019

Pharmacomechanical Catheter-Directed Thrombolysis in Acute
Femoral-Popliteal Deep Vein Thrombosis: Analysis from a
Stratified Randomized Trial
Clive Kearon
McMaster University

Chu-Shu Gu
McMaster University

Jim Julian
McMaster University

Samuel Goldhaber
Harvard Medical School

Anthony Comerota
Inova Alexandria Health Care

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/icts_facpubs

Recommended Citation
Kearon, Clive; Gu, Chu-Shu; Julian, Jim; Goldhaber, Samuel; Comerota, Anthony; Gornik, Heather; Murphy,
Timothy; Lewis, Laurence; Kahn, Susan; Kindzelski, Andrei; Slater, Dennis; Geary, Randolph; Winokur,
Ronald; Natarajan, Kannan; Dietzek, Alan; Leung, Daniel; Kim, Stanley; and Vedantham, Suresh,
"Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis:
Analysis from a Stratified Randomized Trial". Thromb Haemost. 2019. Paper 106.
https://digitalcommons.wustl.edu/icts_facpubs/106

This Article is brought to you for free and open access by the Institute of Clinical and Translational Sciences at
Digital Commons@Becker. It has been accepted for inclusion in ICTS Faculty Publications by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Clive Kearon, Chu-Shu Gu, Jim Julian, Samuel Goldhaber, Anthony Comerota, Heather Gornik, Timothy
Murphy, Laurence Lewis, Susan Kahn, Andrei Kindzelski, Dennis Slater, Randolph Geary, Ronald Winokur,
Kannan Natarajan, Alan Dietzek, Daniel Leung, Stanley Kim, and Suresh Vedantham

This article is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/icts_facpubs/106

The final publication is available at Thieme via https://doi.org/10.1055/s-0039-1677795

Kearon, Clive et al. "Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral–
Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial." doi:10.1055/s0039-1677795.
© Georg Thieme Verlag KG
Stuttgart – New York

Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-popliteal Deep-Vein
Thrombosis: Analysis from a Stratified Randomized Trial

Clive Kearon1; Chu-Shu Gu2; Jim A. Julian2; Samuel Z. Goldhaber3; Anthony J. Comerota4;
Heather L. Gornik5; Timothy P. Murphy6; Laurence Lewis7; Susan R. Kahn8; Andrei L.
Kindzelski9; Dennis Slater10; Randolph Geary11; Ronald Winokur12; Kannan Natarajan13 Alan
Dietzek14; Daniel A. Leung15; Stanley Kim16 ;and Suresh Vedantham17

1: Department of Medicine, McMaster University, Hamilton, ON, Canada;
2: Department of Oncology, McMaster University, Hamilton, ON, Canada;
3: Department of Medicine, Harvard Medical School, Boston, MA, USA;
4: Inova Alexandria Health Care, Alexandria, VA, USA;
5: Department of Medicine, Cleveland Clinic, Cleveland, OH, USA;
6: Department of Diagnostic Imaging, Brown University, Providence, RI, USA;
7: Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA;
8: Department of Medicine, McGill University, Montreal, QC, Canada;
9: Division of Blood Diseases & Resources, National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, MD, USA;
10: Eastern Connecticut Hematology and Oncology Associates, Norwich, CT, USA;
11: Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine,
Winston-Salem, NC, USA; 12Department of Radiology, Weill Cornell Medicine, New York,
NY, USA;
13: St. Vincent Hospital, Indianapolis, IN, USA;
14: Department of Surgery, University of Vermont College of Medicine, Burlington, VT, USA;
15: Department of Radiology, Christiana Care Health Services, Edgemoor, DE, USA;
16: Division of Vascular Surgery, Central DuPage Hospital, Winfield, IL, USA;
17: Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA

Correspondence:
Clive Kearon, Thrombosis and Atherosclerosis Research Institute and Ontario Clinical Oncology
Group, Juravinski Hospital, AE-73, 711 Concession Street, Hamilton, Ontario, L8V 1C3,
Canada.
Telephone: (905) 521-2100 X42426. Fax: (905) 389-0108. E-mail: kearonc@mcmaster.ca

1

Running heading:

PCDT for femoral-popliteal DVT

Key Words:

clinical trial; postthrombotic syndrome; thrombolytic; treatment; venous
thrombosis

Word count

Abstract: 246

Main text: 2836

2

SUMMARY TABLE
What is known on this topic



PCDT did not prevent the post thrombotic syndrome in patients with acute deep vein
thrombosis (DVT) in the ATTRACT trial but improved a number of short- and long-term
secondary outcomes.
It is uncertain if the benefit of PCDT in ATTRACT occurred in patients with femoralpopliteal DVT (defined as femoral DVT that did not involve the common femoral or the iliac
veins).

What this paper adds




Detailed analysis of a broad range of short- and long-term outcomes in 300 patients with
femoral-popliteal DVT.
PCDT did not improve any short- or long-term outcomes, but increased bleeding.
PCDT should not be used as initial treatment of femoral-popliteal DVT.
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Abstract
Background and Objectives: The ATTRACT trial reported that pharmacomechanical catheterdirected thrombolysis (PCDT) did not reduce postthrombotic syndrome (PTS), but reduced
moderate-to-severe PTS and the severity of PTS symptoms. In this analysis, we examine the
effect of PCDT in patients with femoral-popliteal DVT (without involvement of more proximal
veins).
Patients/Methods: Within the ATTRACT trial, 300 patients had deep vein thrombosis (DVT)
involving the femoral vein without involvement of the common femoral or iliac veins and were
randomized to receive PCDT with anticoagulation or anticoagulation alone (No PCDT). Patients
were followed for 24 months.
Results: From 6 to 24 months, between the PCDT vs. No PCDT arms, there was: no difference in
any PTS (Villalta scale ≥5: Risk Ratio [RR]=0.97; 95% confidence interval [CI], 0.75 to 1.24);
moderate-or-severe PTS (Villalta scale ≥10: RR=0.93; 95% CI, 0.57 to 1.52; severity of PTS
scores; or general or disease-specific quality of life (p >0.5 for all comparisons). From baseline
to both 10 days and 30 days, there was no difference in improvement of leg pain or swelling
between treatment arms. From baseline to 10 days, major bleeding occurred in three vs. none
(p=0.06) and any bleeding occurred in eight vs. two (p=0.032) PCDT vs. No PCDT patients.
Over 24 months, recurrent venous thromboembolism occurred in 16 PCDT and 12 No PCDT
patients (p=0.24).
Conclusion: In patients with femoral-popliteal DVT, PCDT did not improve short- or long-term
efficacy outcomes, but it increased bleeding. Therefore, PCDT should not be used as initial
treatment of femoral-popliteal DVT. (NCT00790335).
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Introduction
Pharmacomechanical catheter directed thrombolysis (PCDT), which refers to mechanical
thrombus disruption in combination with thrombolytic therapy, rapidly removes thrombus and
has the potential to improve both short- and long-term outcomes in patients with acute deep vein
thrombosis (DVT). We recently reported the findings of the Acute Venous Thrombosis:
Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) Trial which
compared PCDT with No PCDT (i.e. anticoagulation alone) in patients with acute DVT that
involved the femoral or more proximal veins.(1;2) PCDT did not reduce the primary outcome of
any post thrombotic syndrome (PTS) but reduced the secondary outcomes of moderate-or-severe
PTS and the severity of PTS symptoms and signs. Acutely, PCDT also reduced leg pain and
swelling but increased bleeding.
Among ATTRACT patients, there were important differences in the anatomic extent of
DVT present at randomization, and these differences may have influenced the benefits and risks
of PCDT. For example, patients with more extensive proximal DVT have a higher risk of
recurrence, are more likely to develop PTS, and have more severe PTS than patients with less
extensive DVT.(3;4) To minimize imbalances in the extent of DVT that was present in the PCDT
and No PCDT treatment arms, randomization in ATTRACT was stratified according to the
extent of DVT at diagnosis. In the current analyses, which were pre-planned, we explore the
benefits and risks of PCDT in the subgroup of ATTRACT patients who had femoral-popliteal
DVT without involvement of more proximal deep veins.
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Methods
Study patients and clinical management
The design and main results of ATTRACT have previously been described.(1;2) In brief,
patients 16 to 75 years old with symptomatic DVT that involved the femoral, common femoral,
or iliac veins (with or without other involved veins) were enrolled provided they did not have
symptoms for more than 14 days, high bleeding risk, active cancer, established PTS, or
ipsilateral DVT in the previous 2 years. Patients were enrolled in community and universitybased clinical centers in the US. The study was approved by the research ethics boards of
participating institutions and all patients provided informed consent.
Patients' baseline characteristics, including whether they had iliofemoral or femoralpopliteal DVT, were assessed before randomization. To be included in the femoral-popliteal
randomization stratum and, therefore, eligible for inclusion in the current analysis, patients were
to have thrombus in the femoral (with or without involvement of the popliteal vein) but not the
common femoral vein or the iliac vein.
Patients were randomized in a 1:1 ratio to PCDT or to No PCDT. In addition to
stratification as "femoral-popliteal" and "iliofemoral" DVT, patients were also stratified by
clinical center. Patients in both the PCDT and No PCDT arms received anticoagulant therapy
and elastic compression stockings. PCDT was done using one of three methods. If the popliteal
vein was occluded, patients initially received recombinant tissue plasminogen activator (rt-PA)
infusion through a multi-sidehole catheter for ≤30 hours ("infusion-first" method). If the
popliteal vein was patent, patients initially received rapid delivery of rt-PA through either the
AngioJet Rheolytic Thrombectomy System (Boston Scientific, Marlborough, MA) or the Trellis
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Peripheral Infusion System (Covidien, Inc., Mansfield, MA). After initial delivery of rt-PA,
physicians could use balloon maceration, catheter aspiration, AngioJet or Trellis thrombectomy,
percutaneous transluminal balloon venoplasty, stent placement (iliac or common femoral vein),
continued rt-PA infusion through a multi-sidehole catheter, or a combination of procedures, to
clear residual thrombus and treat obstructive lesions. Stenting of the iliac or common femoral
vein was encouraged if there were obstructive lesions (e.g. extrinsic compression such as MayThurner Syndrome) with ≥50% diameter narrowing, robust collateral filling, or a mean
translesional pressure gradient >2 mmHg . Treatment was discontinued when there was at least
90% thrombus removal with restoration of flow, or a serious complication. The maximum
allowable total dose of rt-PA for initial and follow-up procedures was 35 mg.

Follow-up and outcomes
Study outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months postrandomization. The primary efficacy outcome was the presence of PTS, defined as a Villalta
scale score ≥5 or an ulcer, in the leg with the index DVT, between the 6-month and the 24-month
follow-up visits.(5;6) The Villalta scale rates the severity, from 0 to 3, of five patient-reported
symptoms (pain, cramps, heaviness, pruritus, paresthesia) and six clinician-observed signs
(edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf
compression). Points for symptoms and signs are summed into a total score (range 0-33), and
patients can be categorized as having no PTS (score 0-4), mild PTS (score 5-9), moderate PTS
(score 10-14) or severe PTS (score >14, or presence of ulcer). Patients were also counted as
having PTS if they had an unplanned endovascular procedure to treat severe venous symptoms
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more than 6 months after randomization, unless there was a Villalta <5 in the preceding 4 weeks.
Major non-PTS treatment failures were also assessed.(2)
Using the Villalta scale, the presence of moderate-or-severe PTS (Villalta scale score
≥10, or an ulcer), or severe PTS (Villalta scale score ≥15, or an ulcer) were assessed as
secondary outcomes. Using the Venous Clinical Severity Score (VCSS; ranges from 0 to 27,
with higher scores indicating more severe PTS), the presence of PTS (VCSS ≥4) or severe PTS
(VCSS ≥8) were also assessed.(7) The proportion of patients with a Villalta scale score ≥5 and
≥10, and a VCSS ≥4 and ≥8 at each visit was recorded. The severity of PTS was evaluated at 6,
12, 18 and 24 months using the Villalta scale and the VCSS as continuous measurements. Leg
pain and leg swelling were assessed at baseline, 10 days, and 30 days, using a 7-point Likert pain
scale and by measuring calf circumference.
In the PCDT arm, thrombus removal was quantified using the proximal vein components
of the Marder score (0 to 24, with 24 representing complete thrombosis) by independent central
readers who scored venograms done before and after the procedure.(8)
Safety outcomes included bleeding, recurrent venous thromboembolism, and deaths,
which were reported throughout follow-up and summarized through 10 days.
General health-related quality of life was assessed with the SF-36 Health Status Survey
and venous disease-specific quality of life was assessed with the Venous Insufficiency
Epidemiological and Economic Study (VEINES-QOL) measure.(9;10) Detailed definitions of
trial outcomes have previously been reported.(1;2) Both the clinical personnel who administered
efficacy outcome assessments and the central adjudicators were blinded to treatment allocation.

8

Sample Size
Sample size for the whole ATTRACT study was 692 patients based on the following
assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT
would reduce PTS by at least 33%; 10% loss to follow-up; need to have 80% power to detect the
hypothesized treatment effect; acceptance of a two-side α error of 0.05. We did not prespecify
the proportion of enrolled patients who were expected to have femoral-popliteal DVT, nor did
we require that a minimum number of femoral-popliteal DVT patients be included. A sample
size of 300, corresponding to the number of patients in the current analysis, provides
approximately 80% power to detect a 47% PTS reduction assuming a control proportion of 30%,
and an effect size (i.e. mean difference divided by the standard deviation) of at least 0.32,
assuming a two-sided α=0.05 with each type of analysis.
Statistical Analysis
Two types of analyses were performed: a modified intention-to-treat analysis (primary
analysis) that included all randomized patients except those who did not have DVT at
enrollment; and a per-protocol analysis (secondary analyses) that excluded patients who, within
7 days post-randomization, were randomized to PCDT but did not receive it, or who were
randomized to control but had skin puncture for PCDT thrombolysis or any thrombolytic
therapy.
Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted
for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR)
with their corresponding 95% confidence intervals (CI).
The mean Villalta and VCSS assessments at each visit were estimated using piece-wise
linear regression growth curve models adjusting for clinical center and pre-specified baseline
9

covariates (age, sex, body mass index [BMI], race). Changes from baseline to 10 and 30 days for
leg pain scores and calf circumferences, were compared between the two arms using linear
regression, adjusted for clinical center.
Results
Baseline Characteristics
Of the 692 patients in ATTRACT, 300 (43%) had femoral-popliteal DVT of whom 140
were randomized to PCDT and 160 were randomized to No PCDT (Fig. 1). Median age was 53
years, 73% were male, the index DVT was in the left leg in 59% and symptoms were present for
a median of 7 days. Baseline characteristics were well balanced between the two treatment arms
(Table 1).
Protocol and Treatment Adherence
Within 7 days after randomization, 1 patient assigned to No PCDT had PCDT, and 5
patients assigned to PCDT did not have the procedure (Fig. 1). These patients were excluded
from the per-protocol analysis. PCDT was performed a median of one day post-randomization.
Initial anticoagulant therapy, which was usually low molecular weight heparin or unfractionated
heparin, was similar in the PCDT and No PCDT arms (Table 2).
In PCDT patients, initial rt-PA delivery was with the "infusion-first" method in 66%
(median total rt-PA dose of 22 mg), the AngioJet method in 21% (median total rt-PA dose of 21
mg), and the Trellis method in 9% (median total rt-PA dose of 14 mg); 5% did not recieve rt-PA
(Table 2). After initial rt-PA delivery, additional endovascular methods were used in 85% of
patients (summarized in Table 2). Mean percent thrombus removal, as assessed by pre- and postPCDT venography, was 79% (95% CI, 74% to 83%). The mean pre- and post-lysis Marder
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scores were 10.2 and 2.1 respectively (mean change was -8.1; 95% CI, -7.2 to -8.9; p<0.001).
The mean duration of anticoagulation before first permanent cessation during follow-up, use of
antiplatelet therapy, and use of compression stockings were similar in the PCDT and No PCDT
arms (Table 2).
Primary Efficacy Outcome
PTS, as assessed by a Villalta scale score ≥5 or ulceration, developed in 61 (44%)
patients assigned to PCDT and 71 (44%) patients assigned to No PCDT over 24 months
(RR=0.97; 95% CI, 0.75 to 1.24; p=0.79; Table 3). The findings were similar in a per-protocol
analysis (59 of 135 with PCDT vs. 70 of 159 with No PCDT, RR=0.97; 95% CI, 0.75 to 1.25;
Supplementary Table S1). Results were similar in pre-specified subgroups, except for a
suggestion that the treatment effect of PCDT may have been more favorable in patients with a
major reversible risk factor when the DVT occurred compared to those without such a risk factor
(p interaction=0.04; Fig. 2).
Secondary Efficacy Outcomes
Moderate-or-severe PTS, as assessed by a Villalta scale score ≥10 or ulceration,
developed in 24 (17%) patients assigned to PCDT and 29 (18%) patients assigned to No PCDT
(RR=0.93; 95% CI, 0.57 to 1.52; p=0.77) (Table 3). The findings were similar in a per-protocol
analysis (Supplementary Table S1). Results were similar in pre-specified subgroups except for a
suggestion that the treatment effect of PCDT may have been more favorable in patients with
higher baseline Villalta scores (p interaction=0.03; Fig. 3).
Severe PTS, as assessed by a Villalta scale score ≥15 or ulceration, developed in 10 (7%)
patients assigned to PCDT and 13 (8%) patients assigned to No PCDT (RR=0.84; 95% CI, 0.37
to 1.87; p=0.66; Table 3). Ulceration developed in 3 (2.1%) patients assigned to PCDT and 5
11

(3.1%) patients assigned to No PCDT (Table 3). The proportion of patients who had PTS, or
moderate-or-severe PTS, as assessed by the Villalta scale, at each 6, 12, 18 and 24-month visit
are shown in Table 3; these proportions did not differ between the PCDT vs. No PCDT arms at
any of the follow-up visits. The above findings were similar in a per-protocol analysis
(Supplementary Table S1).
PTS, as assessed by a VCSS ≥4, developed in 43 (31%) patients assigned to PCDT and
50 (31%) patients assigned to No PCDT (RR=0.99; 95% CI, 0.72 to 1.38; p=0.97; Table 3).
Severe PTS, as assessed by a VCSS ≥8, developed in 9 (6%) patients assigned to PCDT and 14
(9%) patients assigned to No PCDT (RR=0.76; 95% CI, 0.35 to 1.65; p=0.49; Table 3). The
findings for these two outcomes were similar in a per-protocol analysis (Supplementary Table
S1).
There was no difference in PTS severity, as assessed by mean Villalta score and mean
VCSS, between the PCDT and No PCDT arm from 6 to 24 months in the modified intention-totreat (Table 4) nor the per-protocol analyses (Supplementary Table S2).
Mean change in leg pain from baseline for PCDT vs. No PCDT was -1.44 vs. -1.35 Likert
points at 10 days (p=0.68), and -1.93 vs. -1.88 Likert points at 30 days (p=0.85). Mean change in
leg circumference from baseline for PCDT vs. No PCDT was 0.45 cm vs. 0.37 cm at 10 days
(p=0.81), and 0.08 cm vs. -0.41 cm at 30 days (p=0.14). The findings for these outcomes were
similar in the per-protocol analyses (Supplementary Table S2).
Mean change in general quality of life and in disease-specific quality of life from baseline
to 30 days and from baseline to 24 months did not differ between the PCDT vs. No PCDT arms
(Table 4 for modified intention-to-treat analysis and Supplementary Table S2 for per-protocol
analysis).
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Safety Outcomes
Within 10 days, in PCDT vs. No PCDT patients, major bleeding occurred in 3 (2.1%) vs.
no patients (p=0.063; none were fatal or intracranial), and any bleeding occurred in 8 (5.7%) vs.
2 (1.3%) patients (p=0.032; Table 3). Recurrent venous thromboembolism within 24 months
occurred in 16 (11%) PCDT vs. 12 (8%) No PCDT patients (p=0.24) (none were fatal). Three
deaths were observed during the study: one in the PCDT arm and 2 in the No PCDT arm. None
occurred within 10 days post-randomization (Table 3).

Discussion
This analysis found that PCDT did not improve any prespecified short-term or long-term
efficacy outcomes but increased bleeding in ATTRACT trial patients who had femoral-popliteal
DVT. Within the femoral-popliteal subgroup of ATTRACT patients, there was a suggestion that
PCDT may have reduced "any PTS" more in patients whose DVT was provoked by a major risk
factor (e.g. recent surgery), and may have reduced moderate-or-severe PTS more in patients who
had higher Villalta scores at baseline. However, as there were many subgroup comparisons and
as the tests of interaction were not strongly statistically significant, it is likely that these two
findings occurred by chance and that the treatment responses did not truly differ between these
subgroups.(11;12) During follow-up, the prevalence of PTS of 44% in both treatment groups
indicates that PTS remains a substantial problem in patients who have femoral-popliteal DVT.
Unlike in the overall study, PCDT did not appear to reduce early symptoms of leg pain or
leg swelling or the occurrence of moderate-or-severe PTS in the femoral-popliteal DVT
subgroup. This suggests that, as we have reported elsewhere, improvements in these outcomes
with PCDT was confined to the iliofemoral DVT subgroup.(13)
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The CAVENT (Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein
Thrombosis) trial, which evaluated 209 patients, reported that catheter-directed thrombolysis
reduced the risk of PTS at 2 and 5 years but did not report findings separately for patients with
femoral-popliteal (required involvement "above mid-thigh level") and iliofemoral DVT.(14;15)
Our analysis has several limitations. As only 43% of ATTRACT trial patients had femoralpopliteal DVT, power to detect difference in outcomes with PCDT vs. No PCDT in the femoralpopliteal subgroup is substantially less than in the overall trial. Furthermore, in the absence of a
statistically significant test of interaction to support a difference in the PCDT treatment effect
between the femoral-popliteal and iliofemoral subgroups, the treatment effect estimate from the
overall trial may be the most reliable estimate of the treatment effect in each of the femoralpopliteal and the iliofemoral subgroups.(11;12) However, as the risk of developing PTS is
influenced by the extent of DVT, it is important to understand outcomes in the ATTRACT
patients whose proximal DVT was confined to the femoral vein.(4) Another limitation is that

more patients were lost to follow-up in the No PCDT arm (28% versus 16%) which has
the potential to reduce the apparent efficacy of PCDT in our analysis. An additional
sensitivity analysis for the primary outcome of any PTS, after using multiple imputation
to replace missing data, found a risk ratio of 0.84 (95%CI, 0.67 to 1.04) for PCDT
compared with control.
A strength of these analyses is that they were prespecified, and that the femoral-popliteal
and iliofemoral subgroups were stratification factors in the randomization of patients to PCDT
and No PCDT. An additional limitation is that differences in the occurrence of PTS between the
treatment groups might emerge with longer than two years of follow-up.
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In conclusion, whereas the overall findings of ATTRACT found suggested that PCDT
reduced moderate-or-severe PTS, reduced the severity of PTS symptoms, and improved recovery
of leg pain and swelling, the current analysis does not support such benefits in patients with
femoral-popliteal DVT. As PCDT is associated with bleeding, early PCDT does not appear to be
warranted in patients with femoral-popliteal DVT without involvement of more proximal veins.
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Table 1: Baseline Characteristics by Treatment Group
Baseline Characteristic
Age, years: median (IQR)
Male: n (%)

PCDT Arm

Control Arm

Total

n = 140

n = 160

N = 300

53 (43, 60)

54 (44, 63)

53 (43, 62)

98

Race: n (%)
White
Black/African-American
Other

(75)

218

(73)

128 (80)

235 (78)

28 (20)

27 (17)

55 (18)

(4)

30 (27, 35)

Symptom severity (Villaltaa) class: n (%)b
None or minimal (score 0-4)

120

107 (76)

5

Body mass index, kg/m2: median (IQR)

(70)

5

(3)

30 (26, 34)

10

(3)

30 (27, 35)

33 (24)

38

(24)

71 (24)

Mild (score 5-9)

50 (36)

59

(37)

109 (36)

Moderate (score 10-14)

38 (27)

38

(24)

76 (25)

Severe (score ≥ 15)

19 (14)

24

(15)

43 (14)

Leg with index DVT, Left: n (%)

83 (59)

93

(58)

176 (59)

Previous DVT or PE: n (%)

35 (25)

42

(26)

77 (26)

Previous ipsilateral DVT: n (%)

2

(1)

4

(3)

6

(2)

DVT risk factors: n (%)c
Major surgery

8

(6)

13

(8)

21

(7)

Hospitalization

9

(6)

9

(6)

18

(6)

Plaster cast immobilization

1

(1)

6

(4)

7

(2)

Outpatient: n (%)
Days from start of DVT symptoms to rand: median (IQR)
eGFR, mL/min: median (IQR)

112 (80)

144 (90)

256 (85)

6 (4, 11)

7 (4, 10)

7 (4, 10)

89 (73, 101)

83 (71, 99)

86 (72, 100)

Leg pain severity: n (%)
0-2

26 (19)

38 (24)

64 (21)

3-4

60 (43)

55 (34)

115 (38)

5-7

53 (38)

65 (41)

118 (39)

Unknown

1

18

(1)

2

(1)

3

(1)

Between-leg circumference differenced, cm: median
(IQR)
Pre-randomization ACe therapy: n (%)c

2 (1, 3)

2 (1, 3)

134 (96)

147 (92)

281 (94)

LMWH

79 (59)

95 (65)

174 (62)

UFH

38 (28)

39 (27)

77 (27)

Rivaroxaban

2 (1, 3)

9

Warfarin

(7)

65 (49)

Other

7

(5)

4

(3)

81 (55)
9

(6)

13

146 (52)
16

IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism; rand, randomization;
eGFR, estimated glomerular filtration rate; LMWH, low molecular weight heparin; UFH, unfractionated
heparin
a

b
c
d
e

Villalta Scale: 5 patient-reported signs (cramps, itching, pins & needles, leg heaviness, pain) and 6
blinded clinician-reported symptoms (pretibial edema, skin induration, hyperpigmentation, venous
ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild,
2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for
each leg
One patient in the control arm were not assessed
Subjects may fit into more than one category
Circumference of leg with index DVT minus circumference of the other leg
Anticoagulant (AC) therapy that was given after DVT diagnosis and before randomization
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(5)

(6)

Table 2: Study Treatments Post Randomization
Treatment over Time
Initial AC a therapy: n (%)b
UFH
LMWH
Other

PCDT Arm
n = 140

Control Arm
n = 160

n = 140

n = 160

45 (32)
82 (59)
18 (13)

At 30 days: n (%)b

27 (17)
95 (59)
41 (26)

n = 138

n = 149

Any AC therapy

138 (100)

149 (100)

Antiplatelet therapy
Compression stockings used ≥ 3 days per week

17 (12)
110 (80)

17 (11)
116 (78)

At 6 months: n (%)b
Any AC therapy
Antiplatelet therapy
Compression stockings used ≥ 3 days per week

n = 121

n = 136

At 24 months: n (%)b

n = 110

Any AC therapy
Antiplatelet therapy
Compression stockings used ≥ 3 days per week
Duration of AC therapy: n (%)

91 (75)
26 (21)
81 (67)
55 (50)
28 (25)
61 (55)
n = 140

Never started
Not stopped during study period
Stopped during study period:
Days to stopping: median (IQR)

0
71 (51)
69 (49)
215 (184, 369)

PCDT Procedure Details (PCDT Arm only)
Initial rt-PA delivery method:
Infusion-First: n (%)

92 (66)

rt-PA total dose, mg: median (IQR)
rt-PA duration, hours: % below 4h, mean (SD) c
AngioJet: n (%)

22 (17, 25)
0%, 21 (5.4)
29 (21)

rt-PA total dose, mg: median (IQR)
rt-PA duration, hours: % below 4h, mean (SD‡
Trellis: n (%)

21 (10, 28)
41%, 20 (5.0)
12

rt-PA total dose, mg: median (IQR)
rt-PA duration, hours: % below 4h, mean (SD)c
Other:d n (%)
20

(9)

14 (11, 23)
75%, 18
(11.7)
7 (5)

120 (88)
15 (11)
89 (65)
n = 106

49 (46)
23 (22)
56 (53)
n = 160

0
90 (56)
70 (44)
223 (190, 300)

Additional endovascular methods used: n (%)
None
1 or more

21 (15)
119 (85)

Type of additional method: n (%)b
Balloon venoplasty
Balloon maceration

57 (48)
78 (66)

Rheolytic thrombectomy (AngioJet)
Stent placement

76 (64)
12 (10)e

Large-bore catheter aspiration

19 (16)

Isolated thrombolysis (Trellis)

3

(3)

b

137 (98)

Ipsilateral popliteal vein
Ipsilateral tibial vein
Ipsilateral common femoral vein
Internal jugular vein

102 (74)
39 (28)
3 (2)
4 (3)

Veins that were accessed: n (%)

Other vein

9

(7)

Marder scores: median (IQR)
Pre lysis
Post lysis

10 (7, 13)
1 (0, 3)

IQR, Inter-quartile range; rt-PA, recombinant tissue plasminogen activator; SD, standard
deviation
a
b
c

d
e

Anticoagulation (AC) therapy given post randomization
Subjects may fit into more than one category
Distributions are bimodal with spikes below 4 hours (means and SDs are for post 4-hour
data)
4 PCDT procedures where there was no acute thrombus on venogram and 3 not attempted
Stents were placed in the iliac vein in 11 patients (reasons: stenosis in 9, extrinsic
compression in 4, not specified in 1) and in the femoral vein in 1 patient (reason: stenosis
and residual thrombosis).
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Table 3: Binary Study Outcomes by Treatment Group (Intention To Treat)

Outcome

PCDT Arm
n = 140
Events

(%)

Control Arm
n = 160
Events

(%)

Risk Ratio
Estimate

95% CI

P
Value

PTS:a
Ulcer (any assessment)

3

(2.1%)

5

(3.1%)

58

(41%)

66

(41%)

0

(0%)

0

(0%)

61

(44%)

71

(44%)

0.97b

0.75, 1.24

0.79

43

(31%)

50

(31%)

0.99b

0.72, 1.38

0.97

At 6 months

28/122

(23%)

45/136

(33%)

0.69

0.46, 1.04

At 12 months

34/117

(29%)

39/121

(32%)

0.90

0.61, 1.32

At 18 months

39/106

(37%)

29/99

(29%)

1.26

0.85, 1.86

At 24 months

31/113

(27%)

34/107

(32%)

0.86

0.57, 1.30

24

(17%)

29

(18%)

0.93

0.57, 1.52

10/122

(8%)

14/136

(10%)

0.80

0.37, 1.73

At 12 months

13/117

(11%)

9/121

(7%)

1.49

0.66, 3.36

At 18 months

13/106

(12%)

11/99

(11%)

1.10

0.52, 2.35

12/113

(11%)

15/107

(14%)

0.76

0.37, 1.54

10

(7.1%)

13

(8.1%)

0.84

0.37, 1.87

0.66

0.35, 1.65

0.49

Villalta ≥ 5 (without ulcer)
Late endovascular procedure only
Total
PTS: VCSS ≥ 4

a

PTS incidence proportion:c

Moderate-severe PTS (Villalta ≥ 10)d
Moderate-severe PTS incidence
proportion:e
At 6 months

At 24 months
Severe PTS: Villalta ≥

15f

Severe PTS: VCSS ≥

8f

0.77

9

(6.4%)

14

(8.8%)

0.76b

0

(0%)

2

(1.3%)

0.23

0.01, 4.72

0.19

61

(44%)

73

(46%)

0.94b

0.73, 1.21

0.65

Major bleeding in first 10 days

3

(2.1%)

0

(0%)

7.99

0.42, 153

0.063

Any bleeding in first 10 days

8

(5.7%)

2

(1.3%)

4.57

0.99, 21.2

0.032

4

(2.9%)

2

(1.3%)

2.29

0.43, 12.3

0.32

16

(11%)

12

(8%)

1.52

0.75, 3.11

0.24

1

(0.7%)

2

(1.3%)

0.57

0.05, 6.23

0.64

Major non-PTS treatment failure
Any treatment failureg

VTE:
First 30 days
Total over 24 months
Death

PTS, post-thrombotic syndrome; CI, confidence interval; VTE, venous thromboembolism
Cumulative proportion of patients who developed PTS (ulcer, Villalta ≥ 5 or LEP) at any time between 6 and
24 months inclusive;
a

b

Cochran-Mantel-Haenszel (CMH) test adjusted for center;

c

At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an
assessment performed (denominator);
d

Cumulative proportion with moderate or severe PTS (pre-specified analysis);
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e

At each visit, the proportion of patients with any moderate or severe PTS according to the Villalta scale
among those who had an assessment performed (denominator);
f

Cumulative proportion with severe PTS;

Composite of PTS or major non-PTS treatment failure. Villalta scores (0-33 range) – higher is worse; VCSS
scores (0-27 range) – higher is worse.
g
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Table 4: Continuous Study Outcomes by Treatment Group (Intention To Treat)
PCDT Arm
n = 140

Outcome

PCDT – Control
Difference

Control Arm
n = 160

n

mean (SE)

n

mean (SE)

Estimate (SE)

P-value

At 6 months

122

2.75 (0.52)

136

3.34 (0.51)

-0.59 (0.44)

0.19

At 12 months

117

2.86 (0.51)

121

3.35 (0.50)

-0.50 (0.42)

0.24

At 18 months

106

2.97 (0.52)

99

3.37 (0.52)

-0.41 (0.45)

0.37

At 24 months

113

3.08 (0.55)

107

3.39 (0.55)

-0.32 (0.53)

0.55

At 6 months

121

1.87 (0.16)

134

2.12 (0.16)

-0.26 (0.22)

0.25

At 12 months

114

At 18 months

105

Villalta mean scorea: (1)

VCSS mean score bc : (2)

At 24 months
SF-36 general Quality of

103

b
b
b

119
94
93

b
b
b

b
b
b

b
b
b

Lifec: (3)

PCS: Change, baseline to 24 months

107 12.00 (0.97)

99

11.03 (0.96)

0.97 (1.22)

0.43

MCS: Change, baseline to 24 months

108

2.34 (0.67)

99

2.75 (0.67)

-0.41 (0.87)

0.63

Overall: Change, baseline to 24 months

108 27.27 (2.04)

99

25.90 (2.01)

1.37 (2.54)

0.59

Symptoms: Change, baseline to 24 months

108 20.60 (2.04)

99

20.14 (2.01)

0.46 (2.52)

0.86

VEINES disease-specific Quality of Lifec: (4)

Leg pain severity§ (7-point scale): (5)
Change, baseline to Day 10

136

-1.44 (0.15)

148

-1.35 (0.15)

-0.09 (0.21)

0.68

Change, baseline to Day 30

136

-1.93 (0.15)

146

-1.88 (0.15)

-0.04 (0.22)

0.85

Change, baseline to Day 10

130

0.45 (0.24)

146

0.37 (0.23)

0.08 (0.33)

0.81

Change, baseline to Day 30

130

0.08 (0.25)

145

-0.41 (0.23)

0.50 (0.34)

0.14

Index leg circumferenced (cm): (6)

a

Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and
piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race)

b

Model estimates are unchanged over visit times due to the lack of a significant time trend

c

Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and
piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race, Villalta score)

d

Mean change scores, SEs, and treatment differences estimated using multiple linear regression adjusted for
center
(1)

Villalta scores (0-33 range) – higher is worse;

(2)

VCSS scores (0-27 range) – higher is worse;

(3)

SF-36 major scales: physical component score (PCS, 0-100 range) and mental component score (MCS, 0100 range) – higher is better, with a difference of 3 to 4 points considered clinically meaningful;
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(4)

VEINES overall score (0-100 range) and symptom specific score (0-100 range) – higher is better;

(5)

patient-reported severity of pain in the index leg (0-7 range) – higher is worse;

(6)

leg circumference measured at 10cm below tibial tuberosity of the index leg.
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Figure Legends

Fig. 1. Patient flow diagram for patients with femoral-popliteal DVT.

PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep-vein thrombosis; LEP,
Late Endovascular Procedure (not including inferior vena cava filter).
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Fig. 2. Subgroup analysis of "any PTS" in patients with femoral-popliteal DVT.

Forest plot of risk ratios (PCDT vs. No PCDT) for the occurrence of PTS from 6 to 24 months
among subgroups of patients. The horizontal lines represent 99% confidence intervals.
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.
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Fig. 3. Subgroup analysis of "moderate-or-severe PTS" in patients with femoral-popliteal
DVT.

Forest plot of risk ratios (PCDT vs. No PCDT) for the occurrence of moderate-or-severe PTS
from 6 to 24 months among subgroups of patients. The horizontal lines represent 99%
confidence intervals.
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.
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